DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone

Information source: Nanjing Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Graves' Disease

Intervention: MMI combined with IID (Drug); MMI (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Xiao-Ming Mao

Official(s) and/or principal investigator(s):
Xiaoming Mao, M.D., Principal Investigator, Affiliation: Affiliated Nanjing First Hospital, Nanjing Medical University

Summary

Antithyroid drugs are widely used in treatment of Graves' disease (GD), but after therapy withdrawal, relapse rate is very high. The aim this trail is to evaluate the effects of intrathyroid injection of dexamethasone combined with antithyroid drugs on patients with newly diagnosed GD.

Clinical Details

Official title: Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: relapse of hyperthyroidism

Detailed description: The morbility of GD is nearly 0. 5% and the underlying cause of 50 to 80% of cases of hyperthyroidism. Recently,anti-thyroid drugs are still the main therapy for Graves'hyperthyroidism in a lot of districts, but the relapse rate is very high (51~68%) after withdrawal of anti-thyroid treatment. In order to reduce the relapse rate, some studies tried to prescribe replacement thyroxine, either with the anti-thyroid drug treatment, or after this was completed, but there is no clear evidence in favour of giving thyroid hormone supplementation following the initial treatment of Graves' thyrotoxicosis with anti-thyroid medication. Therefore, the optimal medical therapy for Graves' hyperthyroidism remains a subject of debate. It is well known that glucocorticoids have anti-inflammatory, immunomodulation and immunosuppression effects and they has long been used to treat GO, and is one of the most effective medicine ,it can decrease some cytokines and reduce inflammatory status ,and improve some thyroid specific antibody, like as thyrotropin receptor antibodies (TRAb), antithyroperoxidase antibodies (TPOAb) and antithyroglobulin antibodies (TGAb).These studies suggested that glucocorticoids might affect autoimmune process and have some benefit effects on GD. Moreover glucocorticoids have been used to treat GD in several early reports, in which serum free triiodothyronine (FT3) and thyroxine (FT4) or total T3(TT3) and TT4 levels decreased after 8 days or three weeks treatment with glucocorticoids . But in those studies, the number of selected patients is small, and the duration of the therapy is relatively short, so that might not confirm the effects of glucocorticoids on GD.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Newly diagnosed of Graves' Disease

Exclusion Criteria:

- Pregnancy

- Allergy to ATD, Alanine aminotransferase (ALT) or asparate aminotransferase (AST)

above 2 times of upper normal range

- Non-compliance because of psychiatric or other serious diseases, or unwillingness to

participate in the study.

Locations and Contacts

Additional Information

Starting date: June 2004
Last updated: May 2, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017